blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2217697

EP2217697 - USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.04.2016
Database last updated on 03.10.2024
Most recent event   Tooltip13.10.2017Lapse of the patent in a contracting state
New state(s): CY, HR, HU, MT, SE, TR		published on 15.11.2017  [2017/46]
Applicant(s)For all designated states
Biogen MA Inc.
250 Binney Street
Cambridge, MA 02142 / US
[2015/24]
Former [2010/33]For all designated states
Biogen Idec MA Inc.
14 Cambridge Center
Cambridge, Massachusetts 02142 / US
Inventor(s)01 / MI, Sha
4 Vernon Road
Belmont, MA 02478 / US
02 / PEPINSKY, R., Blake
30 Falmouth Road
Arlington, MA 02474 / US
03 / MCCOY, John
56 Howard Street
Reading, MA 01867 / US
 [2010/33]
Representative(s)Adams, Harvey Vaughan John, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
[2015/24]
Former [2010/33]Adams, Harvey Vaughan John, et al
Mathys & Squire LLP 120 Holborn London
EC1N 2SQ / GB
Application number, filing date08848257.510.11.2008
[2010/33]
WO2008US12620
Priority number, dateUS20070986492P08.11.2007         Original published format: US 986492 P
[2010/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009061500
Date:14.05.2009
Language:EN
[2009/20]
Type: A1 Application with search report 
No.:EP2217697
Date:18.08.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 14.05.2009 takes the place of the publication of the European patent application.
[2010/33]
Type: B1 Patent specification 
No.:EP2217697
Date:10.06.2015
Language:EN
[2015/24]
Search report(s)International search report - published on:US14.05.2009
(Supplementary) European search report - dispatched on:EP18.01.2013
ClassificationIPC:C12N5/00, A01N37/18, A61K31/70, C07K14/705, A61K38/17, C07K14/46
[2013/08]
CPC:
A61K38/1709 (EP,US); A61K31/70 (EP,US); A61K39/3955 (US);
A61P25/00 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P3/02 (EP); A61P43/00 (EP);
A61P9/00 (EP); C07K14/47 (US); C07K14/70503 (EP,US);
C07K16/18 (US); C12N5/0622 (EP,US); A61K38/00 (EP,US);
A61K48/00 (US); C07K2317/76 (US); C07K2319/30 (US);
C12N2501/998 (EP,US); C12N2502/08 (EP,US); Y02A50/30 (EP,US) (-)
Former IPC [2010/33]C12N5/00, A01N37/18, A61K31/70
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/24]
Former [2010/33]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL08.06.2010
BA08.06.2010
MK08.06.2010
RS08.06.2010
TitleGerman:VERWENDUNG VON LINGO-4-ANTAGONISTEN BEI DER BEHANDLUNG VON LEIDEN MIT DEMYELINIERUNG[2010/33]
English:USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION[2010/33]
French:UTILISATION DES ANTAGONISTES DE LINGO-4 DANS LE TRAITEMENT D'ÉTATS METTANT EN JEU UNE DÉMYÉLINATION[2010/33]
Entry into regional phase08.06.2010National basic fee paid 
08.06.2010Search fee paid 
08.06.2010Designation fee(s) paid 
08.06.2010Examination fee paid 
Examination procedure08.06.2010Examination requested  [2010/33]
07.08.2013Amendment by applicant (claims and/or description)
07.11.2013Despatch of a communication from the examining division (Time limit: M06)
14.05.2014Reply to a communication from the examining division
12.12.2014Communication of intention to grant the patent
22.04.2015Fee for grant paid
22.04.2015Fee for publishing/printing paid
22.04.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.11.2013
Opposition(s)11.03.2016No opposition filed within time limit [2016/20]
Fees paidRenewal fee
24.11.2010Renewal fee patent year 03
23.11.2011Renewal fee patent year 04
26.11.2012Renewal fee patent year 05
27.11.2013Renewal fee patent year 06
26.11.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.11.2008
AT10.06.2015
BE10.06.2015
CY10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
HR10.06.2015
LT10.06.2015
LV10.06.2015
MC10.06.2015
MT10.06.2015
PL10.06.2015
RO10.06.2015
SE10.06.2015
SI10.06.2015
SK10.06.2015
TR10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
IE10.11.2015
LU10.11.2015
CH30.11.2015
LI30.11.2015
[2017/39]
Former [2017/03]AT10.06.2015
BE10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
MC10.06.2015
PL10.06.2015
RO10.06.2015
SI10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
IE10.11.2015
LU10.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/45]AT10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
MC10.06.2015
PL10.06.2015
RO10.06.2015
SI10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
IE10.11.2015
LU10.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/34]AT10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
MC10.06.2015
PL10.06.2015
RO10.06.2015
SI10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
LU10.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/31]AT10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
MC10.06.2015
PL10.06.2015
RO10.06.2015
SI10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
LU10.11.2015
Former [2016/28]AT10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
MC10.06.2015
PL10.06.2015
RO10.06.2015
SI10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
Former [2016/24]AT10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
PL10.06.2015
RO10.06.2015
SI10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
Former [2016/20]AT10.06.2015
CZ10.06.2015
DK10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
PL10.06.2015
RO10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
Former [2016/11]AT10.06.2015
CZ10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
PL10.06.2015
RO10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
Former [2016/10]CZ10.06.2015
EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
PL10.06.2015
RO10.06.2015
SK10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
IS10.10.2015
PT12.10.2015
Former [2016/09]EE10.06.2015
ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
Former [2015/50]ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
BG10.09.2015
NO10.09.2015
GR11.09.2015
Former [2015/49]ES10.06.2015
FI10.06.2015
LT10.06.2015
LV10.06.2015
NO10.09.2015
GR11.09.2015
Documents cited:Search[XY]US2007178088  (WU SHUJIAN [US], et al) [X] 1-12 * sequence 6 * * claims 1-12 * * page 2, column r, paragraphs [13], [14] * * page 6, paragraphs [89], [90], [98]-[102] * * page 144 - page 146; examples 31, 32 * [Y] 1-14
 [Y]  - MI S ET AL, "LINGO-1 Negatively Regulates Myelination by Oligodendrocytes", NATURE NEUROSCIENCE, NATURE AMERICA, INC, US, (20050601), vol. 8, no. 6, doi:10.1038/NN1460, ISSN 1097-6256, pages 745 - 751, XP003005584 [Y] 1-14 * the whole document * * page 746, column l, paragraph l - page 747, column l, line 3 * * page 747, column r, paragraph 3 - page 748, column l, paragraph 2 * * page 748, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1038/nn1460
 [Y]  - MI SHA ET AL, "LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 10, doi:10.1038/NM1664, ISSN 1078-8956, (20070930), pages 1228 - 1233, (20070930), XP002525677 [Y] 1-14 * the whole document * * page 1232, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1038/NM1664
 [Y]  - LEE XINHUA ET AL, "NGF REGULATES THE EXPRESSION OF AXONAL LINGO-1 TO INHIBIT OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, (20070103), vol. 27, no. 1, doi:10.1523/JNEUROSCI.4175-06.2007, ISSN 0270-6474, pages 220 - 225, XP002559457 [Y] 1-14 * the whole document * * page 221, column l, lines 1-14 * * page 222, column l, paragraph 2 - page 223, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.4175-06.2007
 [Y]  - HAINES ET AL, "Expression of the Lingo/LERN gene family during mouse embryogenesis", GENE EXPRESSION PATTERNS, ELSEVIER, AMSTERDAM, NL, (20071022), vol. 8, no. 2, doi:10.1016/J.MODGEP.2007.10.003, ISSN 1567-133X, pages 79 - 86, XP022418642 [Y] 1-14 * the whole document * * page 79, column r, paragraph l - page 81, column l, paragraph 1; figure 1 *

DOI:   http://dx.doi.org/10.1016/j.modgep.2007.10.003
International search[Y]WO2007092370  (WYETH CORP [US], et al);
 [Y]WO2006136006  (UNIV MCGILL [CA], et al);
 [Y]US5605690  (JACOBS CINDY A [US], et al);
 [Y]WO03054152  (HYSEQ INC [US], et al);
 [Y]US2006067935  (AMBATI JAYAKRISHNA [US]);
 [Y]US2007213290  (KINGSMAN ALAN J [GB], et al)
by applicant   - LI; ROLLER, CURR. TOP. MED. CHEM., (2002), vol. 3, pages 325 - 341
    - CAPODICI ET AL., J IMMUNOL, (2002), vol. 169, pages 5196 - 5201
    - CALEGARI ET AL., PROC NATI ACAD SCI USA, (2002), vol. 99, pages 14236 - 14240
    - ZHOU ET AL., NUCLEIC ACIDS RES, (2002), vol. 30, pages 1664 - 1669
    - LEWIS ET AL., NAT GENET, (2002), vol. 32, pages 107 - 108
    - MCCAFFREY ET AL., NATURE, (2002), vol. 418, pages 38 - 39
    - BERTRAND ET AL., BIOCHEM BIOPHYS RES COMMUN, (2002), vol. 296, pages 1000 - 1004
    - LASSUS ET AL., SCI STKE, (2002), page PL13
    - LEIRDAL ET AL., BIOCHEM BIOPHYS RES COMMUN, (2002), vol. 295, pages 744 - 748
    - HOHJOH, FEBS LETT, (2002), vol. 521, pages 195 - 199
    - YANG ET AL., PROC NATL ACAD SCI USA, (2002), vol. 99, pages 9942 - 9947
    - DONZEET ET AL., NUCLEIC ACIDS RES, (2002), vol. 30, page E46
    - YU ET AL., PROC NATL ACAD SCI USA, (2002), vol. 99, pages 6047 - 6052
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.